EP0491708B1 - Isolierung von aminoarginin und verwendung zur blockierung der bildung von stickstoffoxyden im körper - Google Patents

Isolierung von aminoarginin und verwendung zur blockierung der bildung von stickstoffoxyden im körper Download PDF

Info

Publication number
EP0491708B1
EP0491708B1 EP90911378A EP90911378A EP0491708B1 EP 0491708 B1 EP0491708 B1 EP 0491708B1 EP 90911378 A EP90911378 A EP 90911378A EP 90911378 A EP90911378 A EP 90911378A EP 0491708 B1 EP0491708 B1 EP 0491708B1
Authority
EP
European Patent Office
Prior art keywords
arginine
amino
aminoarginine
substance
physiologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90911378A
Other languages
English (en)
French (fr)
Other versions
EP0491708A1 (de
EP0491708A4 (en
Inventor
Owen W. Griffith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Priority to EP96104250A priority Critical patent/EP0719551A3/de
Publication of EP0491708A1 publication Critical patent/EP0491708A1/de
Publication of EP0491708A4 publication Critical patent/EP0491708A4/en
Application granted granted Critical
Publication of EP0491708B1 publication Critical patent/EP0491708B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine

Definitions

  • This invention is directed to novel inhibitors of biological nitric oxide formation.
  • nitroglycerin has been administered to humans as a vasodilating agent in the treatment of cardiovascular disease. Recently, it has been shown that nitroglycerin so administered is converted in the body to nitric oxide which is the pharmacologically active metabolite. Still more recently, nitric oxide has been shown to be formed from arginine as a normal metabolite which is an important component of endothelium-derived relaxing factors (EDRF's). EDRF's are currently being intensively studied as participating in regulation of blood flow and vascular resistance. Incident to such study, a search has been carried out for compounds which block nitric oxide production in the body.
  • EDRF's endothelium-derived relaxing factors
  • N G -methyl-L-arginine (Palmer, R.M.J., et al, Nature (London), 333, pp. 664-666, 1988).
  • Administration of N G -methyl-L-arginine to guinea pigs and rabbits has been shown to increase blood pressure (Aisaka, K., et al, Biochemical and Biophysic Research Communications, Vol. 160, No. 2, pp. 881-886, 4/28/89; Rees, D.D., et al, Proc. Natl Acad. Sci. USA, Vol. 86 , pp. 3375-3378, 5/89).
  • macrophages have also been shown to produce nitric oxide in the body which is a component of their cell killing and/or cytostatic function (Iyengar, R., et al, Proc. Natl. Acad. Sci, USA, Vol. 84 , pp. 6369-6373, 9/87).
  • physiologically active N G -aminoarginine (wherein the terminology N G indicates substitution on a guanidino nitrogen) and its pharmaceutically acceptable acid addition salts constitute superior inhibitors of nitric oxide synthesis in the body.
  • physiologically active N G -aminoarginine is used herein to mean N G -aminoarginine selected from the group consisting of N G -amino-L-arginine and N G -amino-D,L-arginine. In the D,L-compound only the N G -amino-L-arginine portion is physiologically active.
  • N G -amiono-L-arginine has been reported as a by-product in the reductive deprotection of N G -nitro-L-arginine which is used in chemical synthesis of peptides.
  • no report is known of the preparation and isolation of such or of N G -amino-D,L-arginine in pharmaceutically pure form.
  • the invention herein contemplates such preparation and isolation.
  • the present invention relates to a pharmaceutically pure, physiologically active N G -aminoarginine or a pharmaceutically acceptable acid addition salt thereof.
  • composition herein which is considered to be novel is pharmaceutically pure physiologically active N G -aminoarginine or a pharmaceutically acceptable acid addition salt thereof.
  • pharmaceutically pure is used herein to mean 99.9 + % pure (on a water-free basis).
  • the method of the invention herein for preparing and isolating physiologically active N G -aminoarginine comprises the steps of:
  • step (c) is readily carried out by chromatography or by crystallization of the N G -aminoarginine as the flavianic acid salt.
  • a method herein for inhibiting nitric oxide synthesis in a subject in need of such inhibition comprises administering a nitric oxide synthesis inhibiting amount of physiologically active N G -aminoarginine or pharmaceutically acceptable acid addition salt thereof to said subject.
  • subject is used herein to mean any mammal, including humans, where nitric oxide formation from arginine occurs. This method contemplates prophylactic as well as curative use.
  • a method herein for blocking nitric oxide formation from arginine in in vitro studies including studies with isolated organs, intact cells, cell homogenates and tissue homogenates to elucidate or control the biosynthesis, metabolism or physiological role of nitric oxide comprises adding physiologically active N G -aminoarginine or pharmaceutically acceptable acid addition salt thereof to a medium containing said organs, cells, or homogenates at a concentration sufficient to inhibit nitric oxide formation.
  • inventive composition herein constitutes pharmaceutically pure physiologically active N G -aminoarginine or a pharmaceutically acceptable acid addition thereof.
  • N G -amino-L-arginine in free base form has the structural formula
  • N G -amino-D,L-arginine in free base form consists of 50% N G -amino-L-arginine and 50% N G -amino-D-arginine which has the structural formula:
  • the pharmaceutically acceptable acid addition salts are formed initially at the nitrogen with the higher pKa and include, for example, the hydrochloric acid, sulfuric acid, acetic acid, gluconic acid, phosphoric acid, succinic acid, maleic acid, and citric acid addition salts. These are formed by methods well known in the art.
  • N G -aminoarginine for producing N G -amino-L-arginine and N G -nitro,D,L-arginine for producing N G -amino-D,L-arginine.
  • N G -amino-L-arginine is readily commercially available.
  • N G -amino-D,L-arginine is produced the same way as N G -nitro-L-arginine except starting with a D,L-source.
  • the product of step (a) is a mixture of N G -amino-L-arginine and L-arginine.
  • the product of step (a) is a mixture of N G -amino-D,L-arginine and D,L-arginine.
  • Reduction of N G -nitroarginine is readily carried out by reaction of it in solution with hydrogen gas in excess over a suitable reduction catalyst (e.g., Pt on charcoal, PtO, Pd on charcoal, and others well known in the reduction art).
  • Suitable solvents are aqueous acids, e.g., 15% aqueous acetic acid.
  • the reduction reaction is readily carried out at room temperature but temperatures ranging, for example, from 0°C to 100°C or higher can be employed.
  • the reduction reaction proceeds readily at a pressure of 40 psi but can be carried out at pressures ranging from 1 to 2000 psi.
  • step (b) L-arginine is converted to L-ornithine or D,L-arginine is converted to D,L-ornithine.
  • step (b) catalyst is removed, e.g., by filtering, and the solvent is removed, e.g., by rotary evaporation at reduced pressure.
  • the resulting residue is dissolved in water and is adjusted to slightly alkaline pH, e.g., pH ranging from 8 to 10 by addition of base, e.g., NaOH.
  • the arginase (which is readily commercially available) is then added at a concentration ranging, for example, from 0.5 to 5 mg per gram of N G -nitroarginine starting material.
  • Reaction is carried out, for example, by incubation for 8-12 hours at 20° to 40°C, preferably overnight at 37°C.
  • the arginase is removed, e.g., by heat denaturation and centrifugation or filtration, and the resultant product is subject to treatment in step (c).
  • Chromatographic separation in step (c) is readily effected on strong acid cation exchange resin (e.g., Dowex 50 in hydrogen or sodium form) and elution with moderately to strongly basic solutions, e.g., a gradient formed between water and dilute ammonium hydroxide.
  • strong acid cation exchange resin e.g., Dowex 50 in hydrogen or sodium form
  • moderately to strongly basic solutions e.g., a gradient formed between water and dilute ammonium hydroxide.
  • Fractions are collected and analyzed by high performance liquid chromatography (hereinafter HPLC). Appropriate fractions are pooled and the ornithine- and arginine-free product isolated, e.g., by rotary evaporation.
  • step (c) involving crystallization of N G -aminoarginine as the flavianic acid salt
  • this is carried by adding an aqueous solution of flavianic acid (e.g., 6-10 gms/100 ml) until the pH is about 3.8, chilling, for example, to 2-10°C, and collecting the resulting yellow precipitate, e.g., by filtration.
  • an aqueous solution of flavianic acid e.g., 6-10 gms/100 ml
  • the precipitate is recrystallized preferably by successively raising and lowering the pH with NaOH and HCl and a solution of pharmaceutically pure N G -aminoarginine is produced from the recrystallized flavianic salt by stirring said salt with a suspension of strong base anion exchange resin (e.g., Dowex 1) to bind the flavianic acid and release the N G -aminoarginine.
  • a suspension of strong base anion exchange resin e.g., Dowex 1
  • the resin with flavianic acid bound thereto is separated, e.g., by filtering.
  • the pharmaceutically pure physiologically active N G -aminoarginine product is recovered as a solid by evaporating or otherwise drying the filtrate.
  • One group of subjects comprises those with pathologically low blood pressure.
  • One class within this group are those with idiopathic hypotension.
  • Another class within this group are those with drug induced hypotension. In this case coadministration pursuant to the method herein allows use of drugs that otherwise have unacceptable side effects.
  • Still another class within this group are those suffering from shock (including toxic shock syndrome).
  • Another group of subjects comprises those with immune disorders in which down regulation of nitric oxide formation is advantageous, e.g., in auto-immune disorders or in therapeutic immunosuppression for transplant purposes.
  • dosage such depends on the effect desired and the responsiveness of the individual subject.
  • a blood pressure effective raising amount is administered.
  • an immunosuppressive effective amount is administered.
  • dosages range from 10 micrograms per kg to 100 mg/kg, preferably 1 to 10 mg/kg are useful.
  • N G -amino-D,L-arginine the dosage is twice that for N G -amino-L-arginine.
  • Administration is readily carried out, for example, by oral or parenteral routes.
  • N G -aminoarginine is readily administered in combination with typical bulking agents, flavors and the like.
  • media include cardiac perfusion media, tissue culture media, incubation media used with cell or tissue homogenates or purified proteins.
  • the organ treated is typically a blood vessel, lung or kidney.
  • Intact cells include vascular endothelium or macrophages.
  • the homogenates can be, for example, from cardiac, vascular, neural or other tissues and cells.
  • the physiologically active N G -aminoarginine or salt thereof is added to the medium, in a concentration ranging from 1 nanomolar to 300 millimolar.
  • N G -nitro-L-arginine (Sigma Chemicals) was dissolved in 25 ml of 15% aqueous acetic acid with 0.1 gm platinum oxide. The reaction was carried out at 40 psi H 2 pressure and room temperature for about 60 hours. Catalyst was removed by filtration under argon, and the filtrate was rotary evaporated under reduced pressure to an oil. The oil was repeatedly dissolved in water and evaporated under vacuum and finally dissolved in 40 ml water. Analysis indicated 55% N G -amino-L-arginine and 45% L-arginine. The solution was adjusted to pH of 9.5 with NaOH and 5 mg arginase was added (1050 IU).
  • the resulting solution was incubated at 37°C overnight. After this treatment the solution contained N G -amino-L-arginine and L-orthinine but no L-arginine.
  • the arginase was denatured by heating the solution to 100°C for 5 to 10 minutes and removed by filtration. An aqueous solution of flavianic acid (6.28 gm in 100 ml) was added until the pH was about 3.8 and precipitate began to form. The solution was chilled to 40°C overnight to complete precipitation of the product and the precipitate was collected by filtration (about 3.0 gm). The solid was redissolved in hot water (100 ml) by dropwise addition of 1 M NaOH.
  • the monoflavianic acid salt was suspended in 100 ml of water at 100°C and 10 grams of Dowex 1 (OH - ), a strong base ion exchange resin, was added. After stirring at 100°C for 5 hrs the supernatant was clear and all of the yellow flavianic acid was bound to the Dowex 1 resin. The resin was removed by filtration, and the clear filtrate was dried to an oil by rotary evaporation at reduced pressure. The oil was dissolved in 50 ml of ethanol and the ethanol was evaporated at reduced pressure. Addition and removal of ethanol was repeated again, and then 50 ml of ethyl ether was similarly added and removed. The solid residue was dried under high vacuum over P 2 O 5 for 12 hours. The yield was 1.2 grams of pure (99.9 + % pure) N G -amino-L-arginine (35% yield based on starting N G -nitro-L-arginine).
  • N G -nitro-L-arginine (4.38 gm) was reduced to a mixture of L-arginine and N G -amino-L-arginine and treated with arginase as described in Example I.
  • the arginase-free solution was evaporated to dryness and the dried residue was dissolved in 10 ml of water and the resulting solution was applied to a column (2.5 x 45 cm) of Dowex 50 (H + ) resin.
  • the resin was washed with water (500 ml) and then with a linear gradient formed between 1 liter of water and 1 liter of 2 M ammonium hydroxide.
  • a male Hartley guinea pig weighing 500 grams is anesthetized with sodium pentobarbital (50 mg/kg i.p.) and a tracheal cannula is inserted.
  • the left carotid artery is cannulated and connected to a physiological pressure transducer. Blood pressure tracings are displayed on a physiograph. Diastolic blood pressure is monitored following intravenous administration of saline, N G -methyl-L-arginine (0.1, 1 or 10 mg/kg body weight) or N G -amino-L-arginine (0.1, 1 or 10 mg/kg body weight).
  • a separate guinea pig is used for each compound.
  • Vascular relaxation is conveniently studied using isolated rings taken from the aortic or pulmonary vessels of guinea pigs. Addition of acetylcholine to such rings causes synthesis of nitric oxide from L-arginine and the produced nitric oxide causes relaxation of the smooth muscle cells controlling the vascular tone of the vessel ring. Inhibition of nitric oxide formation decreases the relaxant effect of acetylcholine.
  • This in vitro system is a good model for studying chemically induced hypotension due to excessive vascular relaxation.
  • N G -amino-L-arginine The effect of N G -amino-L-arginine on the acetylcholine-mediated relaxation of guinea pig aortic and pulmonary rings was determined as described by the method described in Sakuma, I., et al., Proc. Natl. Acad. Sci. USA 85 , 8664-8667 (1988). The dose of acetylcholine ranged from 10 -8 to 10 -5 M. N G -amino-L-arginine was added at doses of 0, 3 micromolar, 10 micromolar and 30 micromolar.
  • N G -amino-L-arginine In the absence of N G -amino-L-arginine, acetyl-choline at a dose of 10 -8 , 10 -7 , 10 -6 and 10 -5 M caused a relaxation of about 10%, 23%, 43%, and 58%, respectively. Similar studies in the presence of 3 micromolar N G -amino-L-arginine yielded relaxations of 0%, 0%, 5% and 19%. When the concentration of N G -amino-L-arginine was increased to 10 micromolar or 30 micromolar, the extent of relaxation induced by 10 -6 M acetylcholine was ⁇ 1% and that caused by 10 -5 M acetylcholine was ⁇ 10%.
  • N G -methyl-L-arginine was required at concentrations about 5 to 10 fold higher than the listed doses of N G -amino-L-arginine to cause comparable inhibition of vascular ring relaxation.
  • N G -nitro-D,L-arginine When equimolar amounts of N G -nitro-D,L-arginine are substituted for the N G -nitro-L-arginine in Examples I or II, pure N G -amino-D,L-arginine is obtained.
  • N G -amino,D,L-arginine is substituted for N G -amino-L-arginine in twice the dosage or concentration, substantially equal results of diastolic blood pressure increase and inhibition of vascular ring relaxation are obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Water Treatments (AREA)

Claims (23)

  1. Verfahren zur Herstellung von physiologisch aktivem NG-Aminoarginin oder eines pharmazeutisch reinen, pharmazeutisch annehmbaren Säureadditionssalzes von NG-Amino-L-arginin oder Gemischen davon mit NG-Amino-L-arginin in freier Basenform, wobei das Verfahren die Stufen umfaßt:
    (a) Reduktion von NG-Nitro-L-arginin oder NG-Nitro-D,L-arginin unter Bildung eines Gemisches von physiologisch aktivem NG-Aminoarginin und Arginin;
    (b) Behandlung des Gemisches mit Arginase zur Umwandlung des Arginins darin zu Ornithin unter Bildung eines Gemisches aus physiologisch aktivem NG-Aminoarginin und Ornithin;
    (c) Isolierung des pharmazeutisch reinen, physiologisch aktiven NG-Aminoarginins aus dem Gemisch, welches bei der Stufe (b) erhalten wird; und
    (d) gegebenenfalls Umwandlung des NG-Amino-L-arginins in die freie Basenform mit einer pharmazeutisch annehmbaren Säure unter Bildung des Säureadditionssalzes oder eines Gemisches aus NG-Amino-L-arginin in freier Basenform und dem Säureadditionssalz.
  2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das Ausgangsmaterial NG-Nitro-L-arginin ist, das physiologisch aktive NG-Aminoarginin NG-Amino-L-arginin ist, das Arginin L-Arginin ist und das Ornithin L-Ornithin ist.
  3. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die Isolierungsstufe (c) chromatographisch durchgeführt wird.
  4. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die Stufe (c) die Behandlung des Gemisches, welches bei der Stufe (b) anfällt, mit einem Überschuß an Flaviansäure unter Bildung von im wesentlichen reinen NG-Amino-L-argininflaviansäuresalz-Kristallen und die Isolierung des pharmazeutisch reinen NG-Amino-L-arginins aus den Kristallen umfaßt.
  5. Verfahren nach einem der Ansprüche 1, 2, 3 oder 4, dadurch gekennzeichnet, daß das hergestellte Salz ausgewählt wird aus der Gruppe bestehend aus den Chlorwasserstoffsäure-, Schwefelsäure-, Essigsäure-, Gluconsäure-, Phosphorsäure-, Bernsteinsäure-, Maleinsäure- und Zitronensäure-Additionssalzen.
  6. Verfahren zur Herstellung einer Zusammensetzung, umfassend das Vermischen eines Bestandteils, enthaltend mehr als 99,9 Gew.-% (auf wasserfreier Basis) eines Mittels, ausgewählt aus der Gruppe bestehend aus NG-Aminoarginin, enthaltend das L-Enantiomere davon und ein pharmazeutisch annehmbares Säureadditionssalz von NG-Aminoarginin, zusammen mit einem pharmazeutisch annehmbaren Träger oder Verdünnungsmittel.
  7. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß das Mittel NG-Aminoarginin ist, welches das L-Enantiomere davon enthält, wobei das NG-Amionoarginin in freier Basenform vorliegt.
  8. Verfahren nach Anspruch 7, dadurch gekennzeichnet, daß das NG-Aminoarginin 50 bis 100% L-Enantiomeres enthält, wobei irgendein Rest D-Enantiomeres ist.
  9. Verfahren nach Anspruch 7, dadurch gekennzeichnet, daß das NG-Aminoarginin 50% L-Enantiomeres und 50% D-Enantiomeres enthält.
  10. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß das Mittel das pharmazeutisch annehmbare Säureadditionssalz ist und ausgewählt wird aus der Gruppe bestehend aus Chlorwasserstoffsäure-, Schwefelsäure-, Essigsäure-, Gluconsäure-, Phosphorsäure-, Bernsteinsäure-, Maleinsäure- und Zitronensäure-Additionssalzen.
  11. Verfahren nach Anspruch 10, dadurch gekennzeichnet, daß das Mittel das Säureadditionssalz von NG-Aminoarginin ist, welches 50 bis 100% des L-Enantiomeren enthält, wobei der Rest D-Enantiomeres ist.
  12. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß das Mittel ein Säureadditionssalz von NG-Aminoarginin ist, welches 50% L-Enantiomeres und 50% D-Enantiomeres enthält.
EP90911378A 1989-09-13 1990-07-30 Isolierung von aminoarginin und verwendung zur blockierung der bildung von stickstoffoxyden im körper Expired - Lifetime EP0491708B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96104250A EP0719551A3 (de) 1989-09-13 1990-07-30 Isolierung von Aminoarginin und Verwendung zur Blockierung der Bildung von Stickstoffoxyden im Körper

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US406897 1989-09-13
US07/406,897 US5059712A (en) 1989-09-13 1989-09-13 Isolating aminoarginine and use to block nitric oxide formation in body
PCT/US1990/004170 WO1991004023A1 (en) 1989-09-13 1990-07-30 Isolating aminoarginine and use to block nitric oxide formation in body

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP96104250A Division EP0719551A3 (de) 1989-09-13 1990-07-30 Isolierung von Aminoarginin und Verwendung zur Blockierung der Bildung von Stickstoffoxyden im Körper
EP96104250.4 Division-Into 1996-03-18

Publications (3)

Publication Number Publication Date
EP0491708A1 EP0491708A1 (de) 1992-07-01
EP0491708A4 EP0491708A4 (en) 1993-12-29
EP0491708B1 true EP0491708B1 (de) 1997-09-24

Family

ID=23609819

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96104250A Ceased EP0719551A3 (de) 1989-09-13 1990-07-30 Isolierung von Aminoarginin und Verwendung zur Blockierung der Bildung von Stickstoffoxyden im Körper
EP90911378A Expired - Lifetime EP0491708B1 (de) 1989-09-13 1990-07-30 Isolierung von aminoarginin und verwendung zur blockierung der bildung von stickstoffoxyden im körper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96104250A Ceased EP0719551A3 (de) 1989-09-13 1990-07-30 Isolierung von Aminoarginin und Verwendung zur Blockierung der Bildung von Stickstoffoxyden im Körper

Country Status (8)

Country Link
US (1) US5059712A (de)
EP (2) EP0719551A3 (de)
JP (2) JP2728148B2 (de)
AT (1) ATE158505T1 (de)
DE (1) DE69031497T2 (de)
DK (1) DK0491708T3 (de)
ES (1) ES2107427T3 (de)
WO (1) WO1991004023A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802940A (en) * 1982-06-09 1989-02-07 Richland Industrial, Inc. Method for coating pipe with refractory material
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5770623A (en) * 1989-09-13 1998-06-23 Board Of Regents, The University Of Texas System Argine antagonists for inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5312835A (en) * 1989-09-13 1994-05-17 Board Of Regents, The University Of Texas System Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension
US5028627A (en) * 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5710324A (en) * 1990-02-26 1998-01-20 Merrell Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
CA2036770C (en) * 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
US5395612A (en) * 1990-03-27 1995-03-07 Cornell Research Foundation, Inc. Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
US5591613A (en) * 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (de) * 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5273875A (en) * 1991-03-22 1993-12-28 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5132453A (en) * 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5814666A (en) * 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5281627A (en) * 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof
US5585402A (en) * 1992-12-23 1996-12-17 Glaxo Wellcome Inc. Nitric oxide synthase inhibitors
DE4305881C1 (de) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
US5424447A (en) * 1993-07-07 1995-06-13 The Medical College Of Wisconsin Research Foundation, Inc. Heme binding compounds and use thereof
US5358703A (en) * 1993-09-27 1994-10-25 Mcw Research Foundation, Inc. Method for the detection of nitric oxide
ATE222100T1 (de) * 1993-10-21 2002-08-15 Searle & Co Amidino-derivate nützlich als no synthase-hemmer
DE69416848T2 (de) 1993-10-21 1999-07-08 Searle & Co Amidino-derivate als no-synthetase inhibitoren
AU1209995A (en) * 1993-11-17 1995-06-06 Duke University Medical Center Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
WO1995024382A1 (en) * 1994-03-10 1995-09-14 G.D. Searle & Co. L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US5519020A (en) * 1994-10-28 1996-05-21 The University Of Akron Polymeric wound healing accelerators
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
DE793646T1 (de) 1994-11-23 1999-12-30 Upjohn Co Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
US5545625A (en) * 1994-12-12 1996-08-13 The Medical College Of Wisconsin Research Foundation, Inc. Preventing conversion of citrulline to argininosuccinate to limit pathological nitric oxide overproduction
JPH08333258A (ja) 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
WO1996032130A1 (en) * 1995-04-10 1996-10-17 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
ES2206571T3 (es) * 1995-04-20 2004-05-16 G.D. SEARLE & CO. Agentes de amidino ciclico utiles como inhibidores de la oxido nitrico sintasa.
US5830917A (en) * 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) * 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
EP0912523A1 (de) 1996-05-21 1999-05-06 PHARMACIA & UPJOHN COMPANY Aminoguanidin-carboxylat lactame zur behandlung von nicht-insulin abhängiger mellitus
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
EP1086108A1 (de) 1998-06-10 2001-03-28 G.D. Searle & Co. Heterobicyclisch und tricyclisch als no-synthese-inhibitoren
EP1351674A4 (de) 2000-04-12 2004-12-22 Cornell Res Foundation Inc Pharmacotherapie für vaskuläre funktionsstörungen, die mit einer defizitären stickstoffmonoxid-bioaktivität assoziiert sind
FR2808525A1 (fr) * 2000-05-05 2001-11-09 Sod Conseils Rech Applic Nouveaux derives d'aminoacides et leur application a titre de medicaments
WO2001085677A1 (fr) * 2000-05-05 2001-11-15 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'aminoacides et leur application a titre de medicaments
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
MX2012008514A (es) 2010-01-27 2012-08-17 Takeda Pharmaceutical Compuesto para suministrar transtorno de nervio periferico inducido por agente anticancerigeno.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028627A (en) * 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
US4698442A (en) * 1982-12-21 1987-10-06 Syntex (U.S.A.) Inc. ω-Guanidino-substituted-α-amino acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028627A (en) * 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Br.J.Pharm.,47,12-25 (1973) *
Eur.J.Pharm.,141,117-122 (1987) *
Fundamental Immunology, 2ed. pp. 721-733 ,Raven Press Ltd., (1989) *
J.Surg.Res.,38,335-342 (1985) *
Mononuclear Phagocytes, Functional Aspects, Part II, pp. 1106-1141 and 1166-1186, Martinus Nijhoff Publishers (1980) *

Also Published As

Publication number Publication date
DK0491708T3 (da) 1997-12-22
DE69031497D1 (de) 1997-10-30
JPH05500659A (ja) 1993-02-12
JP3009573B2 (ja) 2000-02-14
ATE158505T1 (de) 1997-10-15
JPH07118149A (ja) 1995-05-09
EP0719551A3 (de) 1999-01-27
EP0491708A1 (de) 1992-07-01
ES2107427T3 (es) 1997-12-01
WO1991004023A1 (en) 1991-04-04
JP2728148B2 (ja) 1998-03-18
US5059712A (en) 1991-10-22
EP0719551A2 (de) 1996-07-03
DE69031497T2 (de) 1998-02-05
EP0491708A4 (en) 1993-12-29

Similar Documents

Publication Publication Date Title
EP0491708B1 (de) Isolierung von aminoarginin und verwendung zur blockierung der bildung von stickstoffoxyden im körper
US5158883A (en) Method of using aminoarginine to block nitric oxide formation in vitro
EP0582630B1 (de) N6-(hydrazinoiminomethyl)lysin und verfahren zur hemmung der stickstoffbildung im körper
JP2762522B2 (ja) 血管新生阻害剤
US5750572A (en) Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them
DE69213256T2 (de) Organische salze von n, n'-diacetylcystin
US5436271A (en) N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
JPS5838421B2 (ja) 分岐鎖状ケト酸のオルニチン及びアルギニン塩並びに肝臓及び腎臓障害の治療への使用
BG99609A (bg) Ново арилпропионово производство,метод за неговото получаване и използването му като аналгетично средство
US4749707A (en) Citric acid salt of (+) vinpocetine
CN111635309B (zh) 一种新型解热镇痛药物及其制备方法和用途
US4684482A (en) Orally effective ion chelators
US5547970A (en) Use of leflunomide for inhibiting tumor necrosis factor alpha
US4968671A (en) Therapeutic agents for ischemic heart diseases
US5550249A (en) Water soluble derivatives of biotin and related therapeutical compositions
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
JPS6043351B2 (ja) 老人医学的薬剤の製法
JPS6232170B2 (de)
US4562206A (en) Orally effective inotropic compounds
US5475028A (en) 2-aminoethanesulfonic acid zinc complex
JPS59508B2 (ja) ノウケツカンカクチヨウザイ ２ ３− チカン −４− フクソカンジヨウアミノスルホニルベンゼンスルホンアミド ノ セイホウ
CN116262698A (zh) 一种新的2-(1-羟基戊基)苯甲酸环烷胺盐
JPH0144169B2 (de)
JP2016520538A (ja) 鉄欠乏症および鉄欠乏性貧血の治療および予防のためのＦｅ（ＩＩＩ）錯体
JPS63174931A (ja) 抗アレルギ−剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19931112

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940907

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

DX Miscellaneous (deleted)
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 158505

Country of ref document: AT

Date of ref document: 19971015

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RITSCHER & SEIFERT PATENTANWAELTE VSP

Ref country code: CH

Ref legal event code: EP

ITF It: translation for a ep patent filed

Owner name: STUDIO CONS. BREVETTUALE S.R.L.

REF Corresponds to:

Ref document number: 69031497

Country of ref document: DE

Date of ref document: 19971030

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2107427

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19980724

Year of fee payment: 9

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19990707

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19990714

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19990719

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19990728

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990730

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19990730

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19990915

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19990927

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000730

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000731

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000731

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000731

BERE Be: lapsed

Owner name: CORNELL RESEARCH FOUNDATION INC.

Effective date: 20000731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010201

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed

Ref document number: 90911378.9

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20010201

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20010810

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040615

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20040622

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20040730

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050730

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20050730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060331

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060331